Vicarious Surgical (RBOT) Research & Development (2020 - 2025)

Vicarious Surgical (RBOT) has reported Research & Development for 6 consecutive years, with $8.0 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Research & Development fell 25.99% year-over-year to $8.0 million in Q3 2025; TTM through Sep 2025 was $34.9 million, a 13.05% decrease from a year earlier, with the FY2024 full-year figure at $40.2 million, down 15.6% from the prior year.
• Research & Development was $8.0 million for Q3 2025 at Vicarious Surgical, down from $9.0 million in the prior quarter.
• Over five years, Research & Development peaked at $13.4 million in Q1 2023 and troughed at $3.6 million in Q1 2021.
• A 5-year average of $9.5 million and a median of $9.8 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 212.14% in 2021 and decreased 28.7% in 2023, its largest moves.
• Over 5 years, Research & Development stood at $9.3 million in 2021, then advanced by 28.33% to $11.9 million in 2022, then dropped by 28.7% to $8.5 million in 2023, then decreased by 0.06% to $8.5 million in 2024, then declined by 5.55% to $8.0 million in 2025.
• The last three Research & Development figures came in at $8.0 million (Q3 2025), $9.0 million (Q2 2025), and $9.4 million (Q1 2025), per Business Quant data.